A Review of Current and Emerging Treatment Options for Myelodysplastic Syndromes

A Review of Current and Emerging Treatment Options for Myelodysplastic Syndromes

Friday, December 10, 2021 in Atlanta, GA
Live Meeting -- Marriott Marquis Atlanta, 3:00 PM ET
Atrium A


  • Introduction
  • Therapeutic Approaches for the Treatment of Lower-Risk MDS and Anemia Management
  • Latest Guidance on the Treatment of Higher-Risk MDS and Managing Relapsed/Refractory MDS
  • Novel Strategies Focused on the Stroma and Immunooncology
  • Audience Question and Answer
  • Final Thoughts


Program Director
Michael J. Savona, MD

Beverly and George Rawlings Director of Hematology Research
Hematology, Cellular Therapy and Stem Cell Transplantation
Professor of Medicine and Cancer Biology
Division of Hematology & Oncology
Department of Medicine
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

Jacqueline S. Garcia, MD

Assistant Professor, Medicine
Harvard Medical School
Adult Leukemia Program
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Amer Zeidan, MBBS, MPH

Associate Professor, Internal Medicine
Leader, Leukemia and Myeloid Disease Aligned Research Team (DART)
Director, Hematology Early Therapeutics Research
Yale Cancer Center and Smilow Cancer Hospital
Yale University School of Medicine
New Haven, Connecticut

Goal Statement
The goal of this activity is to improve and accelerate the awareness, understanding, and integration of current and emerging best practices in the treatment of myelodysplastic syndromes.

Target Audience
This program is intended for physicians and other healthcare professionals who care for patients with MDS.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Integrate novel management options for managing MDS-related anemia
  • Evaluate emerging treatment options for the treatment of patients with lower-, intermediate-, and high-risk MDS
  • Consider available treatment options and clinical trial enrollment for the management MDS
  • Plan novel therapeutic options for patients with relapsed/refractory disease
  • Identify patients with MDS who are candidates for ongoing clinical trials


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.